Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Tenax Therapeutics Inc
TENX
Healthcare
Biotechnology
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation...
of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:TENX)
New Post
View:
Posts & Comments
Threaded Posts
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 06, 2024 9:20am
TENX ...... Early a.m runner on NR....big $ financing !!!!
Cha F'king Ching !!!!!!!!
(10)
•••
MikeTester
X
Post by
MikeTester
on Aug 01, 2024 5:50pm
Tenax Therapeutics, Inc. (NASDAQ:TENX): Advancing Levosimend
https://beyondspx.com/2024/08/01/tenax-therapeutics-inc-nasdaqtenx-advancing-levosimendan-for-pulmonary-hypertension-with-promising-clinical-data-and-expanded-ip-protection/
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Jul 02, 2024 12:14pm
TENX .....on watch for slight vol increase & $ appreciation
Over $3 now
(0)
•••
PressRelease
X
Post by
PressRelease
on Feb 29, 2024 9:00am
New Press Release - Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) Presentation will occur at Technology and Heart...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Feb 20, 2024 8:30am
New Press Release - Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
Amendment to existing exclusive license agreement with Orion Corporation expands Tenax’s territory rights from North America, to the entire world Expanded rights position Tenax to engage potential global strategic pharmaceutical partners Improved net sales royalty rate structure, now ranging...
read article.
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Feb 08, 2024 8:58am
TENX.....Nothing lasts forever....Shave & a Haircut P.O
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering 2024-02-08 05:17 ET - News Release CHAPEL HILL, N.C., Feb. 08, 2024 (GLOBE NEWSWIRE
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Feb 08, 2024 8:17am
New Press Release - Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
CHAPEL HILL, N.C., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today the...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Feb 07, 2024 8:01pm
New Press Release - Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Over 40 sites (U.S. and Canada) have agreed to participate in the LEVEL study LEVEL is a randomized, controlled Phase 3 trial of 152 patients, and will recruit patients primarily from leading research centers with large PH-HFpEF populationsTenax forecasts topline LEVEL data will be available...
read article.
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Feb 06, 2024 9:11am
TENX .....Yeeehaaaa ...What a start this a.m
Almost a 300% win Cha F'king Ching !!!!
(105)
•••
Iseneschal
X
Comment by
Iseneschal
on Jan 29, 2024 11:10am
RE:TENX ....I've had this on my "to buy" list
And to add: This is RS #5 All this Co. wants is your money.....you better be selective when u buy this pos
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Jan 29, 2024 11:02am
TENX ....I've had this on my "to buy" list
No position....currently at $13.25 Wouldn't buy it now because .......No Volume It's up on low volume...this could easily reverse on low volume Just my 2 bits There's always another ;
...more
(2)
•••
Ndekanige
X
Post by
Ndekanige
on Jan 28, 2021 4:42pm
Is TENX the next GBR?
Any thoughts ?
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >